J. Moyers

发表

Glucagon as a target for the treatment of Type 2 diabetes

M. Michael, K. Sloop, J. Moyers, 2005, Expert opinion on therapeutic targets.

Internalization and localization of basal insulin peglispro in cells

V. Kiselyov, M. Michael, Liyun Ding, 2017, Molecular and Cellular Endocrinology.

Insulin Resistance – Emerging Therapies for Affected Sites

J. Moyers, J. Caro, 2002 .

Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.

N. Porksen, J. Gromada, B. Berridge, 2004, The Journal of clinical investigation.

In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog

J. M. Beals, M. Farmen, S. D. Kahl, 2016, The Journal of Pharmacology and Experimental Therapeutics.

In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog

J. M. Beals, M. Farmen, S. D. Kahl, 2016, The Journal of Pharmacology and Experimental Therapeutics.

FGF‐21/FGF‐21 receptor interaction and activation is determined by βKlotho

J. D. Dunbar, J. Hale, T. Coşkun, 2008, Journal of cellular physiology.

Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist

M. J. Charron, A. Powers, P. Herrera, 2016, eLife.

Molecular cloning of the human rad gene: gene structure and complete nucleotide sequence.

A. Doria, C. Reynet, J. Moyers, 1996, Biochimica et biophysica acta.

Comprehensive insulin receptor phosphorylation dynamics profiled by mass spectrometry

J. M. Beals, J. Beals, Liyun Ding, 2021, The FEBS journal.

P. Bilan, J. Moyers, C. R. Kahn, 1998, Experimental cell research.

C. Kahn, Jianhua Zhu, P. Bilan, 1997, The Journal of Biological Chemistry.

Rad, a Novel Ras-related GTPase, Interacts with Skeletal Muscle β-Tropomyosin (*)

C. Kahn, D. Antonetti, P. Bilan, 1996, The Journal of Biological Chemistry.

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.

Matthew M. Abernathy, R. Gimeno, F. Willard, 2022, Cell metabolism.

Effects of phosphorylation on function of the Rad GTPase.

J. Zhu, J. Moyers, C. R. Kahn, 1998, The Biochemical journal.

Increased levels of p21ras-GTP and enhanced DNA synthesis accompany elevated tyrosyl phosphorylation of GAP-associated proteins, p190 and p62, in c-src overexpressors.

J. Chang, S. Parsons, J. Moyers, 1993, Oncogene.

Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein

J. M. Beals, J. Beals, R. Hansen, 2022, The Journal of Pharmacology and Experimental Therapeutics.

In vivo and in vitro characterization of basal insulin peglispro: a novel insulin analogue

J. M. Beals, M. Farmen, S. D. Kahl, 2016 .

The sites of phosphorylation by protein kinase C and an intact SH2 domain are required for the enhanced response to beta-adrenergic agonists in cells overexpressing c-src

S. Parsons, A. Bouton, J. Moyers, 1993, Molecular and cellular biology.

Identification and characterization of a cytoskeleton-associated, epidermal growth factor sensitive pp60c-src substrate.

J. Parsons, M. Maa, S. Parsons, 1992, Oncogene.

679-P: The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes

F. Willard, Hongchang Qu, T. Coşkun, 2021, Diabetes.

Overexpression of c-src enhances beta-adrenergic-induced cAMP accumulation.

S. Parsons, D. Luttrell, W. Bushman, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Overexpression of Rad Inhibits Glucose Uptake in Cultured Muscle and Fat Cells*

C. Kahn, P. Bilan, C. Reynet, 1996, The Journal of Biological Chemistry.

FGF-21 as a novel metabolic regulator.

J. Gromada, G. Sandusky, F. Mehrbod, 2005, The Journal of clinical investigation.

Regulation of growth and tumorigenicity of breast cancer cells by the low molecular weight GTPase Rad and nm23.

C. Kahn, P. Watson, Y. Niu, 2001, Cancer research.

Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR®/ABASAGLAR®) approved in the European Union

M. Farmen, Niraj Tripathi, J. Vahle, 2017, Regulatory toxicology and pharmacology : RTP.

Interaction of the Ras-related protein associated with diabetes rad and the putative tumor metastasis suppressor NM23 provides a novel mechanism of GTPase regulation.

C J Rhodes, C. Kahn, B. Zetter, 1999, Proceedings of the National Academy of Sciences of the United States of America.

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

R. Gimeno, D. D’Alessio, K. Bokvist, 2018, Molecular metabolism.

Identification of the in vitro phosphorylation sites on Gs alpha mediated by pp60c-src.

S. Parsons, M. Linder, J. Moyers, 1995, The Biochemical journal.

Molecular determinants of FGF‐21 activity—synergy and cross‐talk with PPARγ signaling

F. Mehrbod, T. Noblitt, J. Moyers, 2007, Journal of cellular physiology.

GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.

V. Pirro, M. Coghlan, R. Gimeno, 2021, The Journal of clinical investigation.

Preclinical Characterization of Once Weekly Basal Insulin Fc (BIF)

J. M. Beals, R. Hansen, Liyun Ding, 2021, Journal of the Endocrine Society.

Structural determinants of dual incretin receptor agonism by tirzepatide

M. Vieth, T. S. Kobilka, B. Kobilka, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once‐weekly dosing for the treatment of patients with diabetes

J. M. Beals, T. Heise, J. Chien, 2022, Diabetes, obesity & metabolism.

Basal Insulin Fc (BIF), A Novel Insulin Suited For Once Weekly Dosing For The Treatment of Patients With Diabetes Mellitus

J. M. Beals, T. Heise, J. Chien, 2021 .

Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors.

N. Noinaj, Zhon-Yin Zhang, M. Michael, 2022, Journal of medicinal chemistry.

Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.

J. Gromada, B. Monia, S. Bhanot, 2004, The Journal of clinical investigation.